{
    "title": "Merck eyes key cancer drug growth as others lose patent protection",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4465634/Drugmaker-Mercks-profit-beats-estimates-margins-rise.html",
    "date": "2017-05-02",
    "keywords": [
        "keytruda",
        "health",
        "drug",
        "lung",
        "percent",
        "quarter",
        "treatment",
        "market",
        "share",
        "cancer",
        "bill",
        "berkrot",
        "grover",
        "company",
        "use",
        "therapy",
        "merck",
        "approval",
        "combination",
        "head",
        "revenue",
        "estimate",
        "loss",
        "competition",
        "growth",
        "inc",
        "tuesday",
        "profit",
        "demand",
        "hepatitis",
        "c",
        "patent",
        "protection",
        "drugmaker",
        "shy",
        "product",
        "secondline",
        "week",
        "chemotherapy",
        "size",
        "analyst",
        "oncology",
        "research",
        "chief",
        "roger",
        "perlmutter",
        "opportunity",
        "neck",
        "indication",
        "forecast",
        "range",
        "view",
        "exchange",
        "environment",
        "exclusivity",
        "cholesterol",
        "cubicin",
        "nasonex",
        "nasal",
        "spray",
        "remicade",
        "europe",
        "vytorin",
        "addition",
        "portfolio",
        "schechter",
        "zepatier",
        "topping",
        "vaccine",
        "papillomavirus",
        "wall",
        "street",
        "thomson",
        "reporting",
        "york",
        "bangaluru",
        "editing"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}